Eton Pharmaceuticals (ETON)
NASDAQ:ETON
Want to see ETON full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.15Last Year’s EPS
-0.1Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum: record product revenue (73% YoY), successful launches of DESMODA and HEMANGEOL, raised full‑year guidance (> $120M), improving adjusted EBITDA and multiple high‑value pipeline milestones (INCRELEX label study cleared, ET‑700 and Amglidia progress). Operational scalability was highlighted by relatively modest G&A growth versus revenue growth. Key risks discussed include launch execution and reimbursement uncertainty for HEMANGEOL (large portion of volume potentially near‑zero revenue), modest margin dilution from ex‑U.S. INCRELEX shipments, higher recurring FDA program fees, and near‑term cash impacts from the HEMANGEOL acquisition. On balance, the positive commercial performance, upgraded guidance, and clear pipeline catalysts outweigh the near‑term uncertainties reported.Company Guidance
Record Quarterly Product Sales and Strong YoY Growth
Product sales and royalty revenue were $24.3M in Q1 2026, representing a 73% year-over-year increase (Q1 2025 product sales $14.0M). Total revenue for the quarter increased 40% to $24.3M versus $17.3M in Q1 2025.
Raised Full-Year Revenue Guidance
Management raised 2026 revenue guidance to exceed $120M (previous guidance $110M), reflecting stronger-than-expected early 2026 trends across the portfolio and contributions from new launches.
Two Major Product Launches (DESMODA and HEMANGEOL)
Launched DESMODA (first/only FDA‑approved desmopressin oral solution) and HEMANGEOL (only FDA‑approved treatment for infantile hemangiomas). DESMODA launch reception strong with potential peak sales estimated at $30M–$50M; HEMANGEOL expected to meaningfully contribute beginning in Q3 and could be the largest product in 2027.
Profitability and Margin Progress
Adjusted EBITDA was $5.7M (24% of revenue) in Q1 2026 versus $3.7M (21%) a year ago (+$2.0M, ~+54%). Management expects full-year adjusted EBITDA margin >30% and is targeting a 50% adjusted EBITDA margin by 2028.
Gross Profit and Margin Targets
Gross profit rose to $14.7M (+49% YoY from $9.9M). Adjusted gross profit was $16.2M (67% of revenue); company reiterates expectation of at least 70% adjusted gross margin for full-year 2026 and 75%–80% in coming years. HEMANGEOL and DESMODA are expected to have above‑average gross margins.
R&D Pipeline Progress and High‑Value Opportunities
Key R&D milestones: FDA cleared INCRELEX label harmonization study (to start H2 2026) — harmonization could expand the U.S. market ~5x; ET‑700 pilot study initiated with topline in H2 2026 and potential >$100M peak sales; KHINDIVI bioequivalence dosing wrapping up with potential supplemental filing in Q3 2026 and approval in Q2 2027; Amglidia IND filed with NDA planned for Q4 2026 (U.S. launch potential in 2027).
Operational Scalability and Cost Discipline
Revenue grew 73% while GAAP G&A increased only 14% (22% on a non‑GAAP basis). Management highlighted that much of the G&A increase was due to loss of orphan PDUFA exemption fees rather than discretionary spend increases, citing scalability of the rare disease commercialization model.
Solid Cash Generation and Improved Financing Terms
Generated $7.4M cash from operations in Q1, paid $14M for the HEMANGEOL acquisition, and finished the quarter with $19.7M cash on hand. Amended $30M credit facility lowered interest by ~200 bps; management expects cash balance to grow during 2026 and to have capacity for accretive product acquisitions.
ETON Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ETON Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2026 | $29.96 | $30.26 | +1.00% |
Mar 19, 2026 | $20.77 | $22.32 | +7.46% |
Nov 06, 2025 | $19.14 | $16.90 | -11.70% |
Aug 07, 2025 | $15.26 | $17.14 | +12.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Eton Pharmaceuticals (ETON) report earnings?
Eton Pharmaceuticals (ETON) is schdueled to report earning on Aug 06, 2026, TBA (Confirmed).
What is Eton Pharmaceuticals (ETON) earnings time?
Eton Pharmaceuticals (ETON) earnings time is at Aug 06, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ETON EPS forecast?
ETON EPS forecast for the fiscal quarter 2026 (Q2) is 0.15.
